As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Beam Therapeutics Inc. The largest reported stake is Fmr LLC's, at 12.6%. 11 filings are on record since August 6, 2025 (Schedule 13G/A, February 5, 2026).
Who owns Beam Therapeutics Inc.?
Sell to companies like Beam Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: ARK Investment Management LLC · Percent: 9.95% · SCHEDULE 13G/A
- · Reporting person: Farallon Capital Management, L.L.C. · Sole voting: 0 · Shared voting: 10,282,210 · Sole dispositive: 0 · Shared dispositive: 10,282,210 · SCHEDULE 13G/A, 2026-08-13
- · Holder: Vanguard Capital Management · Percent: 5.02% · SCHEDULE 13G
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
- · Holder: State Street Corporation · Percent: 5.2% · SCHEDULE 13G
Beam Therapeutics Inc. has 11 Schedule 13D or 13G filings on record since 2025-08-06. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 12.6% | 12,750,369 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 |
| 9.99% | 10,141,856 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 | |
| Farallon Capital Management, L.L.C. | 9.99% | 10,282,210 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| ARK Investment Management LLC | 9.95% | 10,234,862 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| State Street Corporation | 5.2% | 5,228,529 | SCHEDULE 13G, 2026-02-09 | 2025-12-31 |
| Vanguard Capital Management | 5.02% | 5,122,475 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Beam Therapeutics Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Beam Therapeutics Inc. and the records around it.
Beam Therapeutics Inc. elsewhere on the record
Companies that share a holder
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
- ARK Investment Management LLC also filed stake reports on 20 other companies: Tempus AI, Inc. (Nov 2026), 10x Genomics, Inc. (Oct 2026), Twist Bioscience Corp (Sep 2026)
Watch Beam Therapeutics Inc.
Get an email when Beam Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Beam Therapeutics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Beam Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Beam Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Farallon Capital Management, L.L.C. | 0 | 10,282,210 | 0 | 10,282,210 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Partners, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Institutional Partners, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Institutional Partners II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Institutional Partners III, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Four Crossings Institutional Partners V, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Offshore Investors II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital (AM) Investors, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital F5 Master I, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Healthcare Partners Master, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Partners, L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Institutional (GP) V, L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon F5 (GP), L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Healthcare Partners (GP), L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Dapice Joshua J. | 0 | 10,282,210 | 0 | 10,282,210 | SCHEDULE 13G/A, 2026-08-13 |
| Dreyfuss, Philip D. | 0 | 10,282,210 | 0 | 10,282,210 | SCHEDULE 13G/A, 2026-08-13 |
| Dunn Hannah E. | 0 | 10,282,210 | 0 | 10,282,210 | SCHEDULE 13G/A, 2026-08-13 |
| Gehani, Varun N. | 0 | 10,282,210 | 0 | 10,282,210 | SCHEDULE 13G/A, 2026-08-13 |
| Giauque, Nicolas | 0 | 10,282,210 | 0 | 10,282,210 | SCHEDULE 13G/A, 2026-08-13 |
| Husen, Avner A. | 0 | 10,282,210 | 0 | 10,282,210 | SCHEDULE 13G/A, 2026-08-13 |
| Kim, David T. | 0 | 10,282,210 | 0 | 10,282,210 | SCHEDULE 13G/A, 2026-08-13 |
| Linn, Michael G. | 0 | 10,282,210 | 0 | 10,282,210 | SCHEDULE 13G/A, 2026-08-13 |
| Luo Patrick (Cheng) | 0 | 10,282,210 | 0 | 10,282,210 | SCHEDULE 13G/A, 2026-08-13 |
| Roberts, Jr., Thomas G. | 0 | 10,282,210 | 0 | 10,282,210 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Beam Therapeutics Inc. by CUSIP 07373V105 and gives its principal executive office as 238 Main Street, Cambridge, MA 02142 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-06 | Fmr LLC | 15% | SCHEDULE 13G/A |
| 2025-08-07 | ARK Investment Management LLC | 10.35% | SCHEDULE 13G/A |
| 2025-11-05 | Fmr LLC | 13.6% | SCHEDULE 13G/A |
| 2026-02-03 | ARK Investment Management LLC | 12.29% | SCHEDULE 13G/A |
| 2026-02-05 | Fmr LLC | 12.6% | SCHEDULE 13G/A |
| 2026-02-05 | Dapice Joshua J. | 9.99% | SCHEDULE 13G/A |
| 2026-02-09 | State Street Corporation | 5.2% | SCHEDULE 13G |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Capital Management | 5.02% | SCHEDULE 13G |
| 2026-08-13 | Farallon Capital Management, L.L.C. | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | ARK Investment Management LLC | 9.95% | SCHEDULE 13G/A |
Questions about who owns Beam Therapeutics Inc.
Who owns Beam Therapeutics Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Beam Therapeutics Inc.: Fmr LLC (12.6%, Schedule 13G/A, filed 2026-02-05), Dapice Joshua J. (9.99%, Schedule 13G/A, filed 2026-02-05), Farallon Capital Management, L.L.C. (9.99%, Schedule 13G/A, filed 2026-08-13), ARK Investment Management LLC (9.95%, Schedule 13G/A, filed 2026-08-14) and State Street Corporation (5.2%, Schedule 13G, filed 2026-02-09); 1 more is listed above.
Who are the largest shareholders of Beam Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Beam Therapeutics Inc. on this page are Fmr LLC (12.6%), Dapice Joshua J. (9.99%) and Farallon Capital Management, L.L.C. (9.99%).
When did Fmr LLC buy into Beam Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2025-08-06, reporting 15%; its latest, Schedule 13G/A filed 2026-02-05, reports 12.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Beam Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.